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Background
Mycoplasma testing on cell lines or biological products
used to be performed based on classical methods such
as agar and broth medium and/or indicator cell culture.
However, these methods require a long incubation per-
iod and are not adapted for samples, like live-attenuated
vaccine viruses (which can not completely be neutra-
lized) or cell therapy products (with short shelf life).
NAT assays have several advantages including rapid-
time to results, robustness and sensitivity. The European
Pharmacopoeia updated the 2.6.7 section by adding the
detection of Mycoplasma with NAT methods as an
alternative to one or both classical methods.
Texcell’s offers for Mycoplasma testing, which already
included classical methods, were incremended with
NAT assay. For this purpose, 3 commercial kits based
on NAT assay were evaluated based of their claim to
meet the European Pharmacopeia guidance for nucleic
acid amplification techniques for Mycoplasma testing,
including sensitivity and range of detection: CytoCheck
®
from Greiner, MycoTOOL
® from Roche, MycoSEQ
®
Mycoplasma detection kit from Life Technologies.
Material and methods
5 mycoplasma species were chosen among the 9 strains
listed in the European Pharmacopeia.
Mycoplasma Pneumoniae: CIP 103766T
Mycoplasma Hyorhinis: ATCC 179891
Acholeplasma Laidlawii: ATCC 23206
Mycoplasma Orale: provided by Greiner Bio-One
Mycoplasma Synoviae: provided by Greiner Bio-One
1 ml of different concentrations of mycoplasma were
tested according to the supplier’s instructions.
Results
For the mycotool results, none of the mycoplasma spe-
cies tested were detected above the required limit of
detection of 10 cfu/ml. Investigations showed that quan-
tity of nucleic acids in our experimental design was too
small to be efficiently recovered with the precipitation
based extraction procedure. Indeed, the mycoTOOL
®
kit was designed to be used in conjonction with CHO
cells (5x10
6 cells/ml), acting like carrier DNA for the
precipitation step. Since this study, the kit’s supplier has
included a carrier DNA for samples containing low level
of nucleic acid.
Both remaining selected kits (MycoSEQ
® and Cyto-
Check
®) met the sensitivity parameters and were com-
pared (Table 1).
Although these kits use a different technology, similar
results (sensitivity, range of detection) were obtained.
The lower sensitivity observed with the MycoSEQ
® kit
for M. Pneumoniae is explained by the presence of non-
viable mycoplasmas induced during thawing/freezing
cycle for stocks preparation.
According to its safer use (no post-amplification hand-
ling), its lower cost and quantitation possibilities, the
MycoSEQ
® kit was preferred.
Performance validation was conducted in Texcell facil-
ities using the MycoSEQ
® Mycoplasma detection kit.
Conclusion: selection of a high performance kit
and quality improvement
Although two of the selected kits show similar results,
the MycoSEQ
® kit was chosen for its lower risk of cross
contamination. However, all the tested kits (including * Correspondence: dorange@texcell.fr
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extraction controls. Therefore, tests performed systema-
tically at Texcell include viable mycoplasmas (positive
and inhibitory controls). This Texcell’sa d d e dv a l u e
improves the quality of the whole process from the first
concentration step (centrifugation) to the qPCR results.
At Texcell, in 2010, the first samples were tested with
success in a “GMP regulation context”.
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Table 1 Comparison of the MycoSEQ







tested sensitivity <10 CFU/ml <10 CFU/ml 1
Species coverage > 90 41 identified 2
Time to results Same day Same day 3
Contamination prevention No post-amplification sample handling post-amplification sample handling 4
Reagent price ratio per test 1 10 5
Equipment Real-Time PCR 7500 PCR machine scanner 6
quantitation yes no 7
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